EnLyte is intended to address the increased need for metabolically-active form of folate in the cerebrospinal fluid, plasma, and/or red blood cells in patients with MTHFR (all alleles C677T, A1298C and/or G1793A) and/or macrocytic anemia.  EnLyte may be useful in patients at risk of depression due to a deficiency of folate and/or cobalamin.  EnLyte may be taken by patients - ages 12 and up, women of childbearing age, and by geriatric patients where compliance is an issue.

​

Please refer to the Product Information section for full product details.